-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the definition of the National Comprehensive Cancer Network (NCCN), 17% to 31% of newly diagnosed clinically localized prostate cancers are classified as high-risk (Gleason 8-10, or PSA>20 ng/ml, or clinical stage ≥T3)
diagnosis
It is worth noting that when using the JH criteria, compared with HR patients, VHR patients tend to show worse oncology results (biochemical recurrence, metastasis-free survival, and cancer-specific mortality)
When using JH standard, compared with HR patient, VHR patients significantly often exhibit oncology results worse when using JH standard, compared with HR patient, VHR patients significantly often exhibit oncology results worse it is not large Large-scale , population-based analysis to investigate which treatments have advantages in cancer-specific mortality (CSM), especially in JH HR or VHR patients, there is currently no large-scale population-based analysis to investigate which The treatment has advantages in cancer-specific mortality (CSM), especially in JH HR or VHR patients
Recently, researchers from Italy published an article in "J Urol".
They compared radical prostatectomy (RP) with external radiotherapy in the National Comprehensive Cancer Network (NCCN) high-risk (HR) patients and the Johns Hopkins University (JH) high-risk (HR) and very high-risk (VHR) subgroups (EBRT) Cancer-Specific Mortality (CSM) Status They are in the National Comprehensive Cancer Network (NCCN) high-risk (HR) patients and the Johns Hopkins University (JH) high-risk (HR) and very high-risk (VHR) subgroups In, compares the cancer-specific mortality (CSM) of radical prostatectomy (RP) and external radiotherapy (EBRT)
In the surveillance, epidemiology, and final results database (2010-2016), the researchers identified 24,407 NCCN HR patients, of which 10,300 (42%) and 14,107 (58%) were eligible for JH HR and VHR, respectively Standard
CSM of RP and EBRT in patients with NCCN high-risk prostate cancer
CSM of RP and EBRT in patients with NCCN high-risk prostate cancerThe results showed that in the combined NCCN HR cohort, the 5-year CSM rate for RP was 2.
CSM of RP and EBRT in the subgroup of JH extremely high-risk prostate patients
CSM of RP and EBRT in the subgroup of JH extremely high-risk prostate patientsIn summary, the research data shows that in the combined NCCN HR cohort and in its JH VHR patient subgroup, CSM of RP has an advantage over EBRT
In the combined NCCN HR cohort and in the subgroup of JH VHR patients, the CSM of RP has an advantage over EBRT.
Original source:
Francesco Chierigo, Mike Wenzel, Christoph Würnschimmel et al.
Survival after Radical Prostatectomy vs.
Leave a message here